Cover Image

Predicting colorectal cancer survival by combined c-reactive protein and tumor immune score

We evaluated the joint relationship of post-operative C-reactive protein (poCRP) and a tumor immune-cell-score (IS) with overall survival (OS) and CRC-specific survival (CSS) in 680 colorectal cancer (CRC) patients recruited in Germany. CRP was assessed post-surgery while IS was derived from CD3 + /...

Full description

Saved in:
Bibliographic Details
Main Authors: Gwenzi, Tafirenyika (Author) , Wankhede, Durgesh (Author) , Yuan, Tanwei (Author) , Bhardwaj, Megha (Author) , Schrotz-King, Petra (Author) , Anker, Sophie (Author) , Schöttker, Ben (Author) , Hoffmeister, Michael (Author) , Brenner, Hermann (Author)
Format: Article (Journal)
Language:English
Published: 25 November 2025
In: npj precision oncology
Year: 2025, Volume: 9, Issue: 1, Pages: 1-7
ISSN:2397-768X
DOI:10.1038/s41698-025-01192-1
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41698-025-01192-1
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41698-025-01192-1
Get full text
Author Notes:Tafirenyika Gwenzi, Durgesh Wankhede, Tanwei Yuan, Megha Bhardwaj, Petra Schrotz-King, Sophie C. Anker, Ben Schöttker, Michael Hoffmeister and Hermann Brenner
Description
Summary:We evaluated the joint relationship of post-operative C-reactive protein (poCRP) and a tumor immune-cell-score (IS) with overall survival (OS) and CRC-specific survival (CSS) in 680 colorectal cancer (CRC) patients recruited in Germany. CRP was assessed post-surgery while IS was derived from CD3 + /CD8+ cell densities in tumor tissue. Patients were categorized into four C-Reactive protein-Immune cell Score (CRIS) groups: CRIS-1 (CRP-low/IS-high), CRIS-2 (CRP-low/IS-low), CRIS-3 (CRP-high/IS-high), and CRIS-4 (CRP-high/IS-low). Associations of CRIS with survival were assessed using Cox regression, and quantified by hazard ratios with 95% confidence intervals (HR, 95%CI). Subgroup analysis by presence of non-metastatic disease and time of blood draw in relation to adjuvant chemotherapy were conducted. After a median follow-up of 9.6 (IQR, 4.6-14.6) years, 214 (31.5%) patients died, 140 (20.6%) from CRC. Patients in CRIS-4 category had worse prognosis compared to CRIS-1 category [HR(95%CI): 2.01 (1.32-3.08) and 2.60 (1.57-4.32) for OS and CSS, respectively]. These associations were stronger for non-metastatic disease (OSHR = 2.45, CSSHR = 4.49), as well as for patients with blood collected after adjuvant chemotherapy (OSHR = 4.17, CSSHR = 6.62). Integrating post-operative systemic inflammation and tumor immune characteristics may improve prognostic stratification of patients receiving adjuvant chemotherapy for non-metastatic CRC.
Item Description:Gesehen am 03.03.2026
Physical Description:Online Resource
ISSN:2397-768X
DOI:10.1038/s41698-025-01192-1

Similar Items